[1]. Birklein F, Schmelz M: Neuropeptides, neurogenic inflammation and complex regional pain syndrome (CRPS). Neurosci Lett. 2008;437(3):199–202 10.1016/j.neulet.2008.03.081 [PubMed] [CrossRef] [Google Scholar]
[2]. Cui M, Khanijou S, Rubino J, et al. : Subcutaneous administration of botulinum toxin A reduces formalin-induced pain. Pain. 2004;107(1–2):125–33 10.1016/j.pain.2003.10.008 [PubMed] [CrossRef] [Google Scholar]
[3]. Krämer HH, Angerer C, Erbguth F, et al. : Botulinum Toxin A reduces neurogenic flare but has almost no e¬ect on pain and hyperalgesia in human skin. J Neurol. 2003;250(2):188–93 10.1007/s00415-003-0971-x [PubMed] [CrossRef] [Google Scholar]
[4]. Yuan RY, Sheu JJ, Yu JM, et al. : Botulinum toxin for diabetic neuropathic pain: a randomized double-blind crossover trial. Neurology. 2009;72(17):1473–8 10.1212/01.wnl.0000345968.05959. cf [PubMed] [CrossRef] [Google Scholar]
[5]. Ranoux D, Attal N, Morain F, et al. : Botulinum toxin type A induces direct analgesic eects in chronic neuropathic pain. Ann Neurol. 2008;64(3):274–83 10.1002/ana.21427 [PubMed] [CrossRef] [Google Scholar]